As clinicians, teachers, and lifelong learners, we are constantly challenged to convert evolving science into everyday care. This volume is our collective attempt to do precisely that: curate state-of-the-art urological knowledge and distil it into clear, practice-ready guidance for residents, fellows, and practising urologists alike.
A recurring theme across these chapters is precision: the insistence that our diagnoses and decisions be anchored to biology, not merely morphology or habit. The opening chapters on bladder cancer exemplify this shift. Immunohistochemistry is positioned not as a “special stain,” but as a clinical instrument—clarifying CIS versus reactive atypia; enabling luminal–basal subtyping with GATA3 and CK5/6; and improving staging with smoothelin, where millimetres determine treatment. Equally, the focused appraisal of HER2 reminds us that a receptor can be a diagnostic signal, a prognostic lens, and a therapeutic doorway. From antibody-drug conjugates to rational combinations with immunotherapy, the arc is unmistakable: biomarkers are now care pathways.
